



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q2

2025

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO
ANDREAS LÖSLER, CFO

July 30, 2025

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q2 2025

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Strong development continues in 2025; all KPIs as expected



H1 revenue slightly above previous year;
EBITDA with significant growth;



Specialty Chemicals segment pushes figures:
+9% revenue growth
+18% EBITDA growth



Positive free cash flow despite higher investments



Outlook confirmed;
Sales and EBITDA expected to be on record level in 2025



EBITDA margin with further improvements up to 19.6%



Weak USD with impact on p&l



Update on Nitroguanidine expansion

- ✓ Construction activities for Nitroguanidine expansion in Germany are on schedule and within budget; last construction permit received
- ✓ Additional customer grants received
- ✓ Possible sites for US expansion under detailed economical and technical review

AGENDA – ANALYST PRESENTATION Q2 2025

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)




Sales and EBITDA reductions on expected level


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	- 13.2%	- 11.2%
Price	- 2.0%	- 3.2%
Currency	+ 0.3%	+ 0.3%

COMMENTS

- Sales decline of 14% on expected level; mainly resulting from reduced quantities
- Most impact from ongoing weak economics within metallurgical sector in the European steel market
- Electricity costs still higher compared to last year with adverse cost effect on EBITDA
- Chinese competitors with further price reductions to an assumed dumping level
- Promising new products for NITRALZ® business support outlook for second half of 2025
- Inventory level on expected high level in preparation for longer maintenance shut down of carbide furnace



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


Segments growth trend continued




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	+ 16.5%	+ 9.3%
Price	+ 1.5%	- 0.1%
Currency	- 1.3%	- 0.3%

COMMENTS

- The substantial growth in sales and EBITDA was attributed to:
 - **Human Nutrition** – Higher volumes of Creapure® and Creavitalis®
 - **Custom Manufacturing** – Growing demand within the German and European chemical industries
- All other products showed moderate growth or stable development; positive impacts from sales in US
- EBITDA and EBITDA margin improvements follow sales developments with main impacts from come back in custom synthesis



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Regulated grid fees impact sales and result




SALES




EBITDA



SALES



EBITDA



COMMENTS

- Slight reduction in sales development compared to the previous year
- Decreased regulated electricity grid fees for chemical park customers
- Regular chemical park services on prior year level
- EBITDA development mainly resulting from reduced grid fee charges to customers

FINANCIAL OVERVIEW

Robust growth in EBITDA and earnings



Alzchem Group	Q2 2024	Q2 2025	qoq %	2024 1 - 6	2025 1 - 6	yoy %
SALES (in M€)	136.2	142.9	+4.9%	286.3	287.6	+0.5%
EBITDA (in M€)	27.0	29.1	+7.7%	51.9	56.5	+8.7%
EBITDA margin (in %)	19.8%	20.4%	+0.5 pp	18.1%	19.6%	+1.5 pp
Earnings per Share (in €)	1.41	1.57	+10.8%	2.61	3.01	+15.3%

- Sales slightly above prior half-year period and with 5% increase for Q2 stand alone
- Specialty Chemicals segment offsets declines in other segments – volume growth on group level
- High utilization rate leads to improved cost ratio on production level and compensates for increased energy prices
- Personnel expenses now include the full increases stipulated by the collective union agreements from 2024
- Increased sales portion of Specialty Chemicals supports increase in EBITDA as well as EBITDA-margin
- Positive development in net result in line with EBITDA increase

SALES ANALYSIS	DELTA Q2	DELTA 01 - 06
Volume	+5.2%	+1.5%
Price	+0.5%	-0.9%
Currency	-0.7%	-0.1%

BALANCE SHEET & CASHFLOW

Financial situation at positive net cash; increase in total assets



Balance sheet KPIs (T€)	31.12.2024	30.06.2025	Deviation	
Balance sheet total	483,826	552,950	69,124	14.3%
Inventories	101,166	116,934	15,768	15.6%
Equity	207,471	219,322	11,852	5.7%
Equity ratio	42.9%	39.7%	-3.2 pp	
Liabilities to Banks	48,671	44,278	- 4,393	-9.0%
Cash and cash equivalents	61,544	64,275	2,731	4.4%
Net financial debt (-) / asset (+)	12,873	19,997	7,124	55.3%

Cashflow KPIs (T€)	1 - 6 2024	1 - 6 2025	Deviation	
Operating Cashflow	63,829	71,238	7,409	11.6%
Investing Cashflow	- 12,436	- 40,495	- 28,060	225.6%
Free Cashflow	51,394	30,743	- 20,651	-40.2%
Financial Cashflow	- 17,260	- 27,338	- 10,079	58.4%
Net increase in cash	34,134	3,404	- 30,730	-90.0%

COMMENTS

- Increase in balance sheet total resulting from increased CAPEX and customer grants
- Planned inventory increase ahead of carbide furnace maintenance
- Alzchem still shows net financial assets
- Customer grants for Nitroguanidine expansion grow to EUR 51m leading to a stable operating cashflow
- Investing cashflow highly above prior year as Nitroguanidine expansion is on schedule
- Higher dividend payments and share buyback program influence financing cash flow
- Pension obligation on reduced level as interest rates increased to 3.8%

KPI impact of nitroguanidine expansion 1-6/2025 in M€




OUTLOOK 2025 (in M€)


The forecast remains valid – Growth in sales and EBITDA



SALES



EBITDA



COMMENTS

- Outlook for 2025 confirmed
- Major assumptions are still valid
 - No global recession; stable world economy with raw material and logistics costs remain at current levels
 - Electricity prices stay high in first half of 2025
 - No major impacts from the US tariffs policy and no further weakening of US-Dollar
- Sales Growth
 - Organic growth, no acquisitions
 - Specialty Chemicals: Growth mainly through increased volumes of Creapure®, Creamino® and Nitroguanidin
 - Basics & Intermediates: Slight sales decline expected, mainly due to metallurgy / steel industry; Positive trends for NITRALZ®
 - Capacity expansion for Nitroguanidin has no significant impact on 2025 sales
- EBITDA Growth
 - Further increase in higher-margin Specialty Chemical sales will increase EBITDA as well

FINANCIAL CALENDAR

Upcoming dates*



SEP 2	2025	Berenberg Stockholm Seminar
SEP 3	2025	Commerzbank & ODDO BHF Corporate Conference
SEP 9	2025	Berenberg Food Ingredients & Chemicals Conference
SEP 23	2025	Baader Investment Conference
SEP 24	2025	Berenberg and Goldman Sachs Conference
SEP 30	2025	Montega Roadshow Zürich
OCT 30	2025	Quarterly Statement 3rd Quarter 2025
NOV 13	2025	MKK – Münchner Kapitalmarkt Konferenz
NOV 24 – 25	2025	Deutsches Eigenkapitalforum
DEC 2	2025	Berenberg European Conference
JAN 19	2026	Kepler Cheuvreux & UniCredit 25th German Corporate Conference
MAR 5	2026	Berenberg EU Opportunities Conference

*subject to change

FEEDBACK

We appreciate your feedback



Were your expectations met?

Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q2 2025

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group



ALZCHEM GROUP (IN T€)


	31.12.2024	30.06.2025	Deviation	
Intangible assets	3,671	3,587	-84	-2.3%
Tangible assets	192,976	217,682	24,707	12.8%
Investment properties				
Right of use (assets)	4,023	3,323	-700	-17.4%
Investments accounted for using the equity method				
Financial assets	6	6		
Trade receivables				
Other receivables	1,235	11,783	10,548	854.1%
there of Deferred tax assets for pensions provisions				
Deferred tax assets	20,121	17,812	-2,309	-11.5%
SUM NON-CURRENT ASSETS	222,031	254,193	32,162	14.5%
Inventories	101,166	116,934	15,768	15.6%
Trade receivables	78,935	88,096	9,161	11.6%
Financial assets		0	0	
Other receivables	20,080	29,437	9,358	46.6%
Income tax receivables	71	16	-55	-77.5%
Cash and cash equivalents	61,544	64,275	2,731	4.4%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	261,795	298,757	36,962	14.1%
SUM ASSETS	483,826	552,950	69,124	14.3%

ALZCHEM GROUP (IN T€)

	31.12.2024	30.06.2025	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	186,843	199,079	12,236	6.5%
Other comprehensive income	-18,080	-14,945	3,135	-17.3%
Own shares	-1,512	-5,117	-3,605	238.5%
SHARE TO THE SHAREHOLDERS	205,536	217,302	11,766	5.7%
Non-controlling interests	1,934	2,020	85	4.4%
SUM EQUITY	207,471	219,322	11,852	5.7%
Provisions for pensions	96,937	91,644	-5,292	-5.5%
Other provisions	22,209	21,875	-334	-1.5%
Loans	41,082	37,916	-3,166	-7.7%
Finance lease liabilities	2,326	1,689	-638	-27.4%
Trade liabilities		14	14	
Contract liabilities		66,903	66,903	
Other liabilities	647	483	-165	-25.4%
Deferred tax liabilities	7,755	7,934	179	2.3%
SUM NON-CURRENT LIABILITIES	170,956	228,458	57,502	33.6%
Other provisions	3,413	3,573	160	4.7%
Loans	7,589	6,362	-1,227	-16.2%
Finance lease liabilities	1,826	1,752	-74	-4.0%
Finance liabilities	1,994		-1,994	-100.0%
Trade liabilities	37,425	47,586	10,161	27.2%
Contract liabilities				
Other liabilities	39,974	37,252	-2,723	-6.8%
Income tax liabilities	13,178	8,645	-4,533	-34.4%
SUM CURRENT LIABILITIES	105,399	105,170	-230	-0.2%
Sum EQUITY AND LIABILITIES	483,826	552,950	69,124	14.3%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 3.4% to 3.8%
- Pension payments develop as expected with 1.4M€ – pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Deviation (Q2)	
Revenue	150,064	136,191	128,937	139,040	144,680	142,879			6,688	5%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-6,521	12,682	-4,310	-7,169	11,436	3,433			-9,249	-73%
Other income	3,558	3,731	3,716	6,295	5,263	5,006			1,275	34%
Raw materials and consumables used	-53,237	-57,999	-40,548	-43,880	-64,236	-47,293			10,706	-18%
Employee benefits expense	-40,589	-42,468	-38,100	-39,343	-41,150	-44,894			-2,426	6%
Other expense	-28,367	-25,118	-24,813	-26,488	-28,632	-30,036			-4,918	20%
EBITDA	24,910	27,021	24,883	28,455	27,362	29,096			2,076	8%
Depreciation expense	-6,534	-6,453	-6,402	-6,928	-6,552	-6,435			19	0%
Impairment										
EBIT	18,375	20,567	18,480	21,527	20,810	22,662			2,094	10%
Investment income										
Other interest and similar income	292	687	450	801	712	626			-61	-9%
Other interest and similar expense	-1,454	-1,366	-1,537	-1,480	-1,278	-1,284			81	-6%
Financial result	-1,162	-679	-1,087	-679	-567	-658			21	-3%
Result from associates										
Result from ordinary business	17,213	19,888	17,393	20,848	20,243	22,003			2,115	11%
Taxes on income and profit	-4,977	-5,460	-4,974	-5,685	-5,607	-6,128			-667	12%
<i>thereof income tax</i>	-4,463	-5,036	-4,473	-6,148	-4,537	-6,330			-1,293	26%
<i>thereof change from deferred taxes</i>	-514	-424	-501	463	-1,070	202			626	-148%
Annual result	12,237	14,428	12,419	15,163	14,636	15,876			1,448	10%
<i>thereof minority interests</i>	43	43	43	43	43	43				
<i>thereof shares held by shareholders</i>	12,194	14,385	12,376	15,120	14,594	15,832.82			1,448	10%
Result per share in EUR	1.20 €	1.41 €	1.22 €	1.49 €	1.44 €	1.57 €				

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue
Increase (+) / Decrease (-) in inventories of finished goods and work in progress
Other income
Raw materials and consumables used
Employee benefits expense
Other expense
EBITDA
Depreciation expense
Impairment
EBIT
Investment income
Other interest and similar income
Other interest and similar expense
Financial result
Result from associates
Result from ordinary business
Taxes on income and profit
<i>thereof income tax</i>
<i>thereof change from deferred taxes</i>
Annual result
<i>thereof minority interests</i>
<i>thereof shares held by shareholders</i>
Result per share in EUR

Q2 2024	Q2 2025	Deviation (QoQ)	
136,191	142,879	6,688	4.9%
12,682	3,433	-9,249	-72.9%
3,731	5,006	1,275	34.2%
-57,999	-47,293	10,706	-18.5%
-42,468	-44,894	-2,426	5.7%
-25,118	-30,036	-4,918	19.6%
27,021	29,096	2,076	7.7%
-6,453	-6,435	19	-0.3%
0	0	0	
20,567	22,662	2,094	10.2%
0	0	0	
687	626	-61	-8.9%
-1,366	-1,284	81	-6.0%
-679	-658	21	-3.0%
0	0	0	
19,888	22,003	2,115	10.6%
-5,460	-6,128	-667	12.2%
-5,036	-6,330	-1,293	25.7%
-424	202	626	-147.7%
14,428	15,876	1,448	10.0%
43	43	0	0.0%
14,385	15,833	1,448	10.1%
1.41 €	1.57 €	0	10.8%

YTD Jun.2024	YTD Jun.2025	Deviation (YoY)	
286,255	287,559	1,304	0.5%
6,162	14,869	8,708	141.3%
7,290	10,269	2,980	40.9%
-111,236	-111,528	-293	0.3%
-83,056	-86,044	-2,987	3.6%
-53,484	-58,667	-5,183	9.7%
51,930	56,459	4,528	8.7%
-12,988	-12,987	1	0.0%
0	0	0	
38,942	43,471	4,529	11.6%
0	0	0	
979	1,338	358	36.6%
-2,820	-2,563	257	-9.1%
-1,841	-1,225	616	-33.5%
0	0	0	
37,102	42,247	5,145	13.9%
-10,437	-11,735	-1,297	12.4%
-9,499	-10,867	-1,368	14.4%
-938	-868	70	-7.5%
26,664	30,512	3,848	14.4%
85	85	0	0.0%
26,579	30,426	3,848	14.5%
2.61 €	3.01 €	0	15.3%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q2 2024	Q2 2025	1 - 6 2024	1 - 6 2025
Consolidated earnings before taxes	19,888	22,003	37,102	42,247
Depreciation on fixed and intangible assets	6,453	6,435	12,988	12,987
Decrease in pension provisions	-471	-606	-1,104	-1,374
Loss (+) / Profit (-) from the sale of non-current assets	-2	0	-3	22
Other non-cash income (-) and expenses (+)	4,777	1,997	7,887	2,268
Financial result	679	658	1,841	1,225
Interests & Taxes	-2,910	-4,138	-3,863	-7,886
Increase (+) / Decrease (-) Net Working Capital	1,963	-16,132	8,982	-29,256
Payments from customer grants		11,504		51,005
Cashflow from ongoing operations (Net cash flow)	30,379	21,721	63,829	71,238
Cash outflows for investments in fixed assets	-5,543	-27,394	-12,439	-40,534
Cash inflows from the sale of fixed assets	2	-1	3	39
Cash inflows from grants received for investments				
Cashflow from investing activity	-5,541	-27,394	-12,436	-40,495
Free cashflow	24,838	-5,673	51,394	30,743
Deposits (+) / Repayment (-) bank loans long-term				
Repayment of bank loans long-term	-2,208	-2,208	-3,979	-4,416
Deposits (+) / Repayment (-) from short-term financing lines				
Dividend payments	-12,212	-18,190	-12,212	-18,190
Payment of reduction in leasing liabilities	-425	-478	-898	-956
Payments for the acquisition of own shares (incl. transaction costs)		-1		-3,605
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	-14,845	-20,878	-17,260	-27,338
Net increase / decrease in cash and cash equivalents	9,993	-26,551	34,134	3,404

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES


SALES	2023				2024				2025				Deviation PY (Q2)		YTD Q2 2025		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	57,337	46,038	44,271	44,538	49,299	41,848	40,927	41,929	42,638	35,605			-6,242	-15%	91,147	78,244	-12,903	-14%
Specialty Chemicals	85,783	73,172	69,545	91,302	92,961	85,805	80,354	88,969	94,512	100,128			14,323	17%	178,766	194,639	15,873	9%
Other and Holding	7,312	7,389	7,007	6,955	7,804	8,538	7,656	8,142	7,530	7,146			-1,392	-16%	16,342	14,676	-1,666	-10%
Group Consolidation																		
Alzchem Group	150,432	126,599	120,824	142,794	150,064	136,191	128,937	139,040	144,680	142,879			6,688	5%	286,255	287,559	1,304	0%

EBITDA

EBITDA	2023				2024				2025				Deviation PY (Q2)		YTD Q2 2025		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	2,780	2,410	1,065	3,275	1,802	3,055	1,827	4,142	140	1,174			-1,881	-62%	4,857	1,314	-3,543	-73%
Specialty Chemicals	16,019	14,936	18,541	23,747	22,684	22,843	21,749	26,741	26,041	27,854			5,011	22%	45,527	53,895	8,368	18%
Other and Holding	475	438	721	-1,171	537	849	1,114	-711	307	50			-798	-94%	1,386	358	-1,028	-74%
Group Consolidation	-357	88	-793	-802	-113	274	194	-1,717	874	18			-256	-93%	161	892	731	454%
Alzchem Group	18,917	17,872	19,534	25,049	24,910	27,021	24,883	28,455	27,362	29,096			2,076	8%	51,930	56,459	4,528	9%


ALZCHEM GROUP LOCATIONS

Production sites and sales companies



"VERBUND" – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS

POPULATION GROWTH

LONGER LIFE EXPECTANCY

CLIMATE CHANGE

SUSTAINABILITY

SAFETY & DEFENCE

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags. key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		

KEY SHARE DATA

Share details as of July 28, 2025



SHARES OUTSTANDING 10,176,335

LAST CLOSING PRICE EUR 150.2

MARKET CAPITALIZATION EUR 1,528.5 m

TICKER ACT


WKN A2YNT3

ISIN DE000A2YNT30

LISTING Frankfurt Stock Exchange – Prime Standard

DESIGNATED SPONSOR Baader Bank AG
ODDO BHF SE

SHAREHOLDER STRUCTURE



As of July 2025. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices."